Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial Meeting Abstract
| Authors: | Wainberg, Z.; Melisi, D.; Macarulla, T.; Cid, R. P.; Chandana, S.; de la Fouchardiere, C.; Dean, A.; Kiss, I.; Lee, W.; Goetze, T.; Van Cutsem, E.; Paulson, S.; Bekaii-Saab, T.; Pant, S.; Hubner, R.; Xiao, Z.; Chen, H.; Benzaghou, F.; O'Reilly, E. |
| Abstract Title: | Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial |
| Meeting Title: | 25th World Congress on Gastrointestinal Cancer (ESMO 2023) |
| Keywords: | oncology |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Jun 28-Jul 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-06-01 |
| Start Page: | S180 |
| Language: | English |
| ACCESSION: | WOS:001037960400462 |
| DOI: | 10.1016/j.annonc.2023.04.016 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: O-1 -- Source: Wos |
